A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
Clinical trial NCT03519256 · TERMINATED
Trial details
- NCT number
- NCT03519256
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-02
- Primary completion
- 2022-08-22
- Enrollment
- 142
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.